Pancreatic Neuroendocrine Tumor
Oncology·MeSH: Adenoma, Islet Cell
Prevalence
30.0 / 100K
4 drugs in development·3 companies·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| CABOMETYX | EXELIXIS, INC. (EXEL) |
Phase 1(1)
| Drug | Company |
|---|---|
| zanzalintinib | EXELIXIS, INC. (EXEL) |
Unknown(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Pancreatic Neuroendocrine Tumor?
BioSniper tracks 4 drugs in development for Pancreatic Neuroendocrine Tumor across 3 companies.
How many clinical trials target Pancreatic Neuroendocrine Tumor?
There are 3 clinical trials targeting Pancreatic Neuroendocrine Tumor tracked by BioSniper.
What is the prevalence of Pancreatic Neuroendocrine Tumor?
The estimated prevalence of Pancreatic Neuroendocrine Tumor is approximately 30.0 per 100,000 population.
Deep-dive into Pancreatic Neuroendocrine Tumor
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis